{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T02:13:36.446129+00:00","company":{"ticker":"FULC","cik":1680581,"company_name":"Fulcrum Therapeutics, Inc."},"pagination":{"limit":100,"returned":8,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"restructuring_charge","fact_key":"4296be21b5966dc23705415330674bb539aeaaff","cik":1680581,"ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2026-06-04T20:05:17+00:00","payload":{"affected_area":null,"charge_text":"approximately $4.2 million","effective_date":"2026-05-31","event_type":"restructuring","headcount_text":"approximately 85%, from 57 full-time employees to 9 full-time employees","item_codes_triggered":["2.05"]},"claim":"Fulcrum Therapeutics, Inc. announced a restructuring with charges of approximately $4.2 million (approximately 85%, from 57 full-time employees to 9 full-time employees).","evidence_excerpt":"On May 31, 2026, the board of directors of Fulcrum Therapeutics, Inc., or Fulcrum, approved a restructuring plan to significantly reduce Fulcrum’s operating expenses and preserve capital following the discontinuation of development of pociredir for the treatment of sickle cell disease, or SCD. The restructuring plan will reduce Fulcrum’s workforce by approximately 85%, from 57 full-time employees to 9 full-time employees, and is expected to be substantially completed during the second quarter of 2026. Fulcrum expects to incur aggregate charges of approximately $4.2 million in connection with the restructuring plan, consisting primarily of employee severance, employee benefits and related costs.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-257376","anchor_url":"https://secwatch.observer/filing/0001193125-26-257376#claim-4296be21b5966dc23705415330674bb539aeaaff","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526257376/0001193125-26-257376-index.htm"},{"fact_type":"earnings_release","fact_key":"aa48098a738dd0a50f37e4fa3ed9c99888cb8b5b","cik":1680581,"ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2026-04-27T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$18.9 million","period_text":"first quarter of 2026","report_date":"2026-04-27","result_type":"reported_results","revenue_text":null},"claim":"Fulcrum Therapeutics, Inc. reported first quarter of 2026 results: net income $18.9 million.","evidence_excerpt":"higher employee compensation costs, including $0.3 million of increased stock-based compensation expense, as well as higher professional services costs. • Net Loss: Net loss was $18.9 million for the three months ended March 31, 2026, compared to a net loss of $17.7 million for the three months ended March 31, 2025. Cash Runway Guidance Based on its current operating","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-26-178806","anchor_url":"https://secwatch.observer/filing/0001193125-26-178806#claim-aa48098a738dd0a50f37e4fa3ed9c99888cb8b5b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526178806/0001193125-26-178806-index.htm"},{"fact_type":"material_agreement","fact_key":"7438de5fd1b870b56fc4b094280e6bc8273e66ea","cik":1680581,"ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2026-04-27T23:59:59+00:00","payload":{"action":"termination","agreement_name":"CAMP4 License","agreement_type":"license","counterparty":"CAMP4 Therapeutics Corp.","effective_date":"2026-04-23","item_codes_triggered":["1.02"],"value_text":null},"claim":"Fulcrum Therapeutics, Inc. terminated CAMP4 License with CAMP4 Therapeutics Corp. (effective 2026-04-23).","evidence_excerpt":"On April 23, 2026, Fulcrum Therapeutics, Inc., or Fulcrum, provided written notice to CAMP4 Therapeutics Corp., or CAMP4, of termination of the License Agreement dated July 5, 2023, between Fulcrum and CAMP4, or the CAMP4 License, which termination will be effective in accordance with the terms of such agreement.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-178806","anchor_url":"https://secwatch.observer/filing/0001193125-26-178806#claim-7438de5fd1b870b56fc4b094280e6bc8273e66ea","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526178806/0001193125-26-178806-index.htm"},{"fact_type":"executive_change","fact_key":"4e58232dbc","cik":1680581,"ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-11-12","interim":false,"role":"director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Rachel King was appointed as director at Fulcrum Therapeutics, Inc..","evidence_excerpt":"On November 12, 2024, the Board, upon the recommendation from the Nominating and Corporate Governance Committee, appointed Rachel King as a member of the Board, with immediate effect to fill the vacancy created by Dr. Collins' resignation.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-256101","anchor_url":"https://secwatch.observer/filing/0001193125-24-256101#claim-4e58232dbc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312524256101/0001193125-24-256101-index.htm"},{"fact_type":"executive_change","fact_key":"fc7f201149","cik":1680581,"ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2024-11-12T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-11-12","interim":false,"role":"director","role_category":"director","successor_name":"Rachel King","successor_named":true},"claim":"James J. Collins resigned as director at Fulcrum Therapeutics, Inc..","evidence_excerpt":"On November 12, 2024, James J. Collins, a Class II director, notified the board of directors, or the Board, of Fulcrum Therapeutics, Inc., or Fulcrum, of his decision to resign as a member of the Board and all committees thereof, with immediate effect.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001193125-24-256101","anchor_url":"https://secwatch.observer/filing/0001193125-24-256101#claim-fc7f201149","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312524256101/0001193125-24-256101-index.htm"},{"fact_type":"executive_change","fact_key":"77009ace72","cik":1680581,"ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2024-06-17T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-06-17","interim":false,"role":"Class I Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Colin Hill was elected as Class I Director at Fulcrum Therapeutics, Inc..","evidence_excerpt":"elected Colin Hill as a member of the Board, effective June 17, 2024","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001193125-24-162653","anchor_url":"https://secwatch.observer/filing/0001193125-24-162653#claim-77009ace72","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312524162653/0001193125-24-162653-index.htm"},{"fact_type":"earnings_release","fact_key":"2238a9f5626836b7f96b54fdedd9415e5372f993","cik":1680581,"ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"Net loss was $26.9 million for the three months ended March 31, 2024","period_text":"first quarter of 2024","report_date":"2024-05-13","result_type":"reported_results","revenue_text":null},"claim":"Fulcrum Therapeutics, Inc. reported first quarter of 2024 results: net income Net loss was $26.9 million for the three months ended March 31, 2024. Guidance reaffirmed.","evidence_excerpt":"Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024","confidence":0.45,"filing_url":"https://secwatch.observer/filing/0000950170-24-058187","anchor_url":"https://secwatch.observer/filing/0000950170-24-058187#claim-2238a9f5626836b7f96b54fdedd9415e5372f993","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1680581/000095017024058187/0000950170-24-058187-index.htm"},{"fact_type":"material_agreement","fact_key":"8f46192acfb0be0a42a45815442ad4df4640630d","cik":1680581,"ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","filed_at":"2024-05-13T23:59:59+00:00","payload":{"action":"entry","agreement_name":null,"agreement_type":"collaboration","counterparty":"Genzyme Corporation, a wholly-owned subsidiary of Sanofi","effective_date":"2024-05-11","item_codes_triggered":["1.01"],"value_text":"$80.0 million"},"claim":"Fulcrum Therapeutics, Inc. entered into a collaboration with Genzyme Corporation, a wholly-owned subsidiary of Sanofi valued at $80.0 million (effective 2024-05-11).","evidence_excerpt":"On May 11, 2024, Fulcrum Therapeutics, Inc., or Fulcrum, entered into a collaboration and license agreement with Genzyme Corporation, a wholly-owned subsidiary of Sanofi, or Sanofi, pursuant to which Fulcrum granted Sanofi an exclusive license under certain intellectual property rights to commercialize losmapimod, an oral small molecule for the treatment of facioscapulohumeral muscular dystrophy, or FSHD, outside of the United States.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000950170-24-058187","anchor_url":"https://secwatch.observer/filing/0000950170-24-058187#claim-8f46192acfb0be0a42a45815442ad4df4640630d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1680581/000095017024058187/0000950170-24-058187-index.htm"}]}